On January 20, 2026 Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, reported Peter Melnyk has joined the company as President & Chief Operating Officer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Mr. Melnyk comes to Taiho Oncology with more than 30 years of proven experience in oncology commercialization and leadership across pharmaceuticals, medical devices and biotech sectors. Mr. Melnyk joined Taiho Oncology from Alpha Tau Medical, where he was the Chief Commercial Officer and former board member and led the global commercialization efforts for a novel alpha-emitting radiotherapeutic. He was also the CEO of Fortovia Therapeutics and drove the transformation and portfolio expansion in oncology supportive care. In addition, Mr. Melnyk was the Chief Commercial Officer at Novocure, where he built the global commercial infrastructure and launched Optune, a novel medical device for the treatment of glioblastoma. He also held senior leadership roles at OSI/Astellas, Pharmacia/Pfizer and Bristol-Myers Squibb and holds a Master of Science and Bachelor of Science from McGill University.
"We are excited to welcome Peter to Taiho Oncology as President & Chief Operating Officer," said Tim Whitten, CEO of Taiho Oncology. "Peter is an innovator with a demonstrated track record of success. We believe his strong leadership capabilities and ability to deliver measurable results will help guide Taiho Oncology’s continued growth and innovation as we pursue our mission of improving the lives of patients with cancer, their families and their caregivers."
"It’s a privilege to join Taiho Oncology, a company with a remarkable legacy of scientific innovation, commercial excellence, patient-centered care and an exceptional culture – one that values integrity, collaboration, and the relentless pursuit of better outcomes for patients," Mr. Melnyk said. "I’ve spent my career working to bring transformative oncology treatments to patients around the world. What excites me most about Taiho is the combination of deep scientific expertise, a mission-driven collaborative culture, and a shared commitment to making a difference for patients and their families."
(Press release, Taiho, JAN 20, 2026, View Source [SID1234662106])